Search

Displaying results 721 - 730 of 2960 in total
  1. Drug

    Efmoroctocog alfa

    go.drugbank.com/drugs/DB11607
    ApprovedInvestigational

    rFVIII-Fc fusion protein (rFVIIIFc) where the conjugated molecule of rFVIII to polyethylene glycol is covalently fused to the dimeric Fc domain of human immunoglobulin G1, a long-lived plasma protein [FDA

  2. Drug

    Riboflavin

    go.drugbank.com/drugs/DB00140
    ApprovedInvestigationalNutraceuticalVet approved

    Nutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables. The richest natural source is yeast. It occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms ...

    Mixtures: Vp-heme Ob, Cavan Heme OB
  3. Drug

    Cefaclor

    go.drugbank.com/drugs/DB00833
    ApprovedInvestigational

    Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.

    Products: CEFACLOR EG, Nu-cefaclor
  4. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States.

  5. Drug

    Guselkumab

    go.drugbank.com/drugs/DB11834
    ApprovedInvestigational

    Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade...

  6. Drug

    Atractylodes lancea root oil

    go.drugbank.com/drugs/DB14338
    Approved

    Atractylodes lancea root oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: OHUI Sun Science Sun Block EX plus Beige
  7. Drug

    Nalmefene

    go.drugbank.com/drugs/DB06230
    ApprovedInvestigationalWithdrawn

    [L40684] The nasal spray formulation of nalmefene was approved by the FDA in May 2023.[L46511] … [L40684] It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor.

  8. Drug

    Dasabuvir

    go.drugbank.com/drugs/DB09183
    Approved

    Approved in December 2014 by the FDA, Viekira Pak is indicated for the treatment of HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] [FDA Label]. … Dasabuvir is a non-nucleoside NS5B inhibitor which binds to the palm domain of NS5B and induces a conformational change which renders the polymerase unable to elongate viral RNA [FDA Label].

  9. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    Lack of significant side effects and short duration of therapy is a considerable advantage over older interferon-based regimens, which were limited by infusion site reactions, reduced blood count, and … Within Canada and the United States, paritaprevir is currently available in three fixed dose products: Viekira Pak (FDA), Technivie (FDA and Health Canada), and Holkira Pak (Health Canada).

    Synonyms: (2R,6S,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo
  10. Drug

    Uridine triacetate

    go.drugbank.com/drugs/DB09144
    Approved

    Like many other neoplastic agents, these side effects limit the doses of 5-FU that can be administered, which also affects the efficacy for treatment. … By pre-administering with uridine (as the prodrug uridine triacetate), higher doses of 5-FU can be given allowing for improved efficacy and a reduction in toxic side effects [A18578].